logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
09/02/2026
Caxif Life Sciences Company: The company has signed an exclusive license and supply agreement with Intes Pharmaceuticals for a complex peptide product in Europe, the UK, and India.
Latest
3 m ago
New York period silver rose 7% intra-day, now trading at $82.28 per ounce.
4 m ago
Standard & Poor's: Downgrade Raizen to junk status, seventh grade.
4 m ago
HSBC strategist sees no sustained selling pressure on US stocks, bullish on cyclical sectors.
5 m ago
UBS CEO: The Swiss response to the Swiss credit crisis was emotional.
6 m ago
The Food and Drug Administration (FDA) stated that a television commercial for Novo Nordisk's (NVO.N) new weight loss drug contains "false or misleading" claims about the weight loss effects of the drug, exacerbating the challenges faced by the pharmaceutical company recently. The FDA said that the TV commercial "misleadingly" implies that the oral form of Wegovy has advantages over other weight loss medications. In a letter to Novo Nordisk on February 5, the agency specifically questioned the claims of "living lightly" and "bright future" that appeared in the advertisement. "Furthermore, these claims misleadingly imply benefits beyond actual weight loss, such as emotional relief, reduced psychological burden, bringing hope or direction to patients' lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific disease," the FDA said.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.